![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
EDITORIAL COMMENT
Minerva Urology and Nephrology 2021 October;73(5):674-6
DOI: 10.23736/S2724-6051.21.04762-5
Copyright © 2021 EDIZIONI MINERVA MEDICA
language: English
Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration?
Francesco DEL GIUDICE 1, 2 ✉, David D’ANDREA 3, Andrea MARI 4, Francesco SORIA 5, Wojciech KRAJEWSKI 6, Marco MOSCHINI 7, on behalf of the YAU Urothelial Working Group
1 Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy; 2 Department of Urology, Stanford Medical Center, Stanford, CA, USA; 3 Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 4 Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Florence, Italy; 5 Division of Urology, Department of Surgical Sciences and Urology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy; 6 Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, University Center of Excellence in Urology, Wroclaw, Poland; 7 Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy